Navigation Links
Gemcitabine in Medical News

Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer

(PHILADELPHIA) A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research , published by researchers at Thomas Jefferson University. The protein, called Hu antigen R (HuR), is a stres...

Chemotherapy with gemcitabine delays progression of operable pancreatic cancer

Barcelona, Spain: Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists. The study, presented today (Thursday) at the European Cancer Conference (ECCO 14) in Barce...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

... ongoing randomized Phase 2 studies, including a trial to evaluate Nexavar plus paclitaxel in the first-line setting, a trial to evaluate Nexavar plus gemcitabine or capecitabine in the first- or second-line setting following progression on bevacizumab, and a trial to evaluate Nexavar plus docetaxel and/or letro...

New drug candidate prolongs the lives of pancreatic cancer patients

...tic cancer patients was 10.8 months better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting o...h advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed o...

US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...progression-free survival (PFS), the objective response rate (ORR), and to further evaluate the safety and tolerability of BSI-201 in combination with gemcitabine and carboplatin. Phase II of the study in triple negative breast cancer patients found that BSI-201 + G/C resulted in a statistically and cli...

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

... doxorubicin will be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer For advanced cervical cancer, the combination of gemcitabine + cisplatin will be the new standard-of-care concerning choice of chemotherapy. Maintenance therapy in Non-Small Cell Lung Cancer: ...

New Insights, Inroads Against Breast, Ovarian Cancers

...l cancer. In one study, led by Dr. Alfonso Duenas-Gonzalez of Mexico's National Cancer Institute, researchers found that adding the chemotherapy drug gemcitabine (Gemzar) to standard chemo and radiation therapy improved both progression-free and overall survival -- but not without notable side effects. And ...

Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer

...-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not recommended in t...c cancer, Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with loca...ens-Johnson syndrome. Patients taking Tarceva plus gemcitabine were more likely to experience bleeding and clotti...

A New Way to Get Chemo to Pancreatic Tumors

...In the study, researchers genetically engineered mice to develop a form of pancreatic cancer. The scientists then gave them a chemotherapy drug called gemcitabine (Gemzar) and another compound they hoped would boost blood flow in the tumors. The survival time of the mice, on average, doubled from 11 to 25 da...

Amgen Highlights Data to Be Presented at ASCO

... anticancer therapies in a variety of tumors. A phase 1b study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients with metastatic pancreatic cancer (PC) Lead Author: Kindler HL Abstract No. 4501 (Saturday, May 30, 2009, 8:30am-8:4...
Gemcitabine in Medical Technology

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

Results are basis for CTI's Marketing Authorization Application currently under review by the EMEA SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) today announced the publication of results from its randomized phase III trial ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...progression-free survival (PFS), the objective response rate (ORR), and to further evaluate the safety and tolerability of BSI-201 in combination with gemcitabine and carboplatin. Phase II of the study in triple negative breast cancer patients found that BSI-201 + G/C resulted in a statistically and cli...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

...in two separate U.S. Phase II studies." The investigators examined in vitro combination effects of reovirus alone and in combination with cisplatin, gemcitabine or vinblastine. When reovirus was used alone, it demonstrated significant cytolytic activity in 7 of 9 NSCLC cell lines examined. The combinations dem...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...ences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that act...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

...vival at three years for patients treated with the gemcitabine chemoradiation combination versus those treated on...tion (74% vs. 65%, respectively). Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities. Additionally, two patients on the gemcitabine arm died due to causes possibly attributed to trea...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

... Teneriello, M.D., Texas Oncology-Austin Central, co-chair, US Oncology Gynecologic Cancer Research Committee: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Interim analysis of inducti...

Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)

...ty Hospital Gasthuisberg, Leuven, Belgium. "The interesting results show the need for further exploring which patients benefit from the combination of gemcitabine plus Avastin and Tarceva in view of the statistically longer PFS which trends towards improved survival." The results of the phase III AVITA (BO1770...

Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations

...red to drug delivery involving paclitaxel at its maximum tolerated dose. In addition, preclinical studies involving a drug conjugate of paclitaxel and gemcitabine co-formulated into nanoparticles showed that a synergistic ratio of the two drugs circulating in plasma was maintained for more than 24 hours after in...

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

... of non-inferiority and the STELLAR 3 study as supportive of the MAA. In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduc...

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

...ntibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer. The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutio...
Gemcitabine in Biological News

TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer

...tophagy. In a separate paper, they showed that silencing TG2 with the siRNA liposome reduced tumor size, slowed metastasis and enhanced the effect of gemcitabine chemotherapy. "This aberrant protein is doing so many different things, you would have to develop a small-molecule drug to block each function," Me...

Death, division or cancer? Newly discovered checkpoint process holds the line in cell division

...xel and gemcitabine, exploit the mechanisms of mitosis to kill cancer cells. Although they act through very different mechanisms, both paclitaxel and gemcitabine sabotage the events monitored by the checkpoint proteins, which then leads to cell death. According to Yen, a deeper understanding of the mechanisms o...

2 new therapies show promise for cancer patients

...c cancer have a very poor survival, and until now, the only option has been gemcitabine alone or in combination with erlotinib, said Von Hoff. The researchers u...rial is dramatic, Von Hoff said. The rationale behind the combination of gemcitabine plus Abraxane was based on careful science and was designed and executed by...

Dealing deadly cancers a knockout punch

... reported at the American Association for Cancer Research Annual Meeting in April, 2007. In mice transplanted with a human colon cancer, Reolysin plus gemcitabine completely eradicated the tumors in four of five test animals. It is rare to see the virtual elimination of tumours as well as the long-lasting thera...
Gemcitabine in Biological Technology

Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation

TAINAN, Taiwan, July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ("Lilly") and ScinoPharm Taiwan Ltd. ("ScinoPharm") announced today that they have reached an amicable resolution of all ongoing patent litigations between the companies relating to ScinoPharm's manufacture and sale of gemcit...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

... than 24 weeks. Patient enrolment was completed in May; - Presented a poster at ASCO demonstrating that the combination of REOLYSIN and gemcitabine in a U.K. Phase I trial was well tolerated, and resulted in disease control for a majority of the patients. Of the ten patients evalua...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

...itled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and gemcitabine (GEM) in Patients (pts) with Advanced Cancer." The results, which were prev... announced in March 2009, demonstrated that the combination of REOLYSIN and gemcitabine was well tolerated, and resulted in disease control for a majority of the p...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...randomized Phase 2 trial comparing two dose levels of PX-12 in up to 80 patients at three sites with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen was initiated in January 2007. Enrollment in this trial was terminated in early 2009. The Company intends to seek ...

Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference

...lleagues are scheduled to deliver a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and gemcitabine (GEM) in Patients (pts) with Advanced Cancer." - Dr. Sanjay Goel and colleagues are scheduled to deliver a poster entitled "Dos...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

...onomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen Produces Enhanced Activity in Metastatic Renal Cell Carcinoma: A Phase 2 Study of Sorafenib, gemcitabine and Metronomic Capecitabine in Patients with Advanced mRCC Joaquim Bellmunt, M.D., Chief of the Solid Tumor Oncology Section, Medical O...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

...May 31, 2009, 10:30 a.m. A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis ... Abstract #4503: Oral Presentation: June 1, 2009, 4:30 p.m. gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic bil...

Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial

... administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers incl...e of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metasta...domized study of REOLYSIN given intravenously with gemcitabine every three weeks....

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

...bserved when adding OGX-011 to first- line gemcitabine and a platinum-containing chemotherapy when compar... randomized phase 3 trials evaluating first-line gemcitabine and a platinum-containing chemotherapy in ...ison, published studies using a first-line gemcitabine and platinum-based chemotherapy for advanced ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

...4%. For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of ...olerated, and toxicities were consistent with the adverse event profile for gemcitabine in combination with a platinum-based regimen in this population. Serum cl...
Other Tags
(Date:7/26/2014)... The European gas chromatography reagents report defines and ... of revenue. The gas chromatography reagents market in Europe is ... to grow to around $445.5 million by 2018, at a ... through the TOC of the European gas chromatography reagents market, ... report also provides a glimpse of the segmentation of gas ...
(Date:7/26/2014)... 26, 2014 “Today, we introduce our ... clients all over the world. All these models are ... designed for the UK market,” says the CEO of ... suppliers of women’s special occasion outfits. , Ladies have ... comes. DressesOnlineShops.co.uk is one of the best choices for ...
(Date:7/26/2014)... 2014 According to the ... Vkool.com, this is a comprehensive guide that ... treating all types of disorders related ...     Tinnitus due to Ménière's disease , ... pathway tinnitus ,     Inner, middle or ...
(Date:7/26/2014)... 2014 Studio B Dental in Toronto now ... called Teeth in a Day, gives patients the opportunity to ... of bright, pearly whites with very little recovery time and ... and feel just like natural teeth, and require no special ... Studio B Dental is one of the premiere dental experts ...
(Date:7/26/2014)... According to the Metabolic Enhancement Training program review ... program that helps men lose body fat and build ... program also instructs men how to melt fat and ... in its review that this program includes a series ... ripped and jacked at the same time. Vkool also ...
Breaking Medicine News(10 mins):Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3
(Date:7/25/2014)... Florida , July 25, 2014 ... more consumers are turning to digital technology for online ... (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ), ... (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ...
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... has different effects on different species of fish, ... of Bristol and Exeter which tested fish anti-predator ... a flying seagull predator model when exposed to ... European minnows. , Lead author Dr Irene ... "Noise levels in many aquatic environments have increased ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
Other Contents